Pathogenesis and Novel Targeted Therapies of Psoriasis

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 1713

Special Issue Editor


E-Mail Website
Guest Editor
National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Interests: psoriasis; biologic treatment; microbiome; alopecia; hair loss; systemic sclerosis; lupus; atopic dermatitis; immunosupressants
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic and recurrent immune-mediated skin disease with a prevalence of approximately 2–3% worldwide. According to current knowledge, psoriasis is a systemic, multifactorial disease that develops in genetically predisposed individuals under various environmental factors. Recently, a large number of studies have highlighted the role of gut and skin microbiota in the onset and progression of psoriasis.

Despite undisputed achievements in basic and clinical sciences over the last few decades, we still do not fully understand this disease. The complexity of psoriasis is also affected by the several comorbidities, including metabolic syndrome, cardiovascular diseases, psoriatic arthritis or depression.

This Special Issue is now open to contributions, and aims to explore the latest updates of all aspects of psoriasis including its pathogenesis, biomarkers, comorbidities and therapy.

We look forward to receiving your best original and review papers.

Dr. Mariusz Sikora
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • genetics
  • immunology
  • therapy
  • biologics
  • biomarkers
  • microbiota
  • comorbidities
  • skin
  • IL-23/IL-17 axis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

7 pages, 722 KiB  
Communication
A Possible Link between Gut Microbiome Composition and Cardiovascular Comorbidities in Psoriatic Patients
by Virginia Valentini, Valentina Silvestri, Agostino Bucalo, Federica Marraffa, Maria Risicato, Sara Grassi, Giovanni Pellacani, Laura Ottini and Antonio Giovanni Richetta
J. Pers. Med. 2022, 12(7), 1118; https://doi.org/10.3390/jpm12071118 - 09 Jul 2022
Cited by 5 | Viewed by 1429
Abstract
Cardiovascular disease (CVD) is one of the most common comorbidities that may affect psoriatic patients. Several exogenous and endogenous factors are involved in the etiology and progression of both psoriasis and CVD. A potential genetic link between the two diseases has emerged; however, [...] Read more.
Cardiovascular disease (CVD) is one of the most common comorbidities that may affect psoriatic patients. Several exogenous and endogenous factors are involved in the etiology and progression of both psoriasis and CVD. A potential genetic link between the two diseases has emerged; however, some gaps remain in the understanding of the CVD prevalence in psoriatic patients. Recently, the role of the gut microbiome dysbiosis was documented in the development and maintenance of both diseases. To investigate whether gut microbiome dysbiosis might influence the occurrence of CVD in psoriatic patients, 16S rRNA gene sequencing was performed to characterize the gut microbiome of 28 psoriatic patients, including 17 patients with and 11 without CVD. The comparison of the gut microbiome composition between patients with and without CVD showed a higher prevalence of Barnesiellaceae and Phascolarctobacterium in patients with CVD. Among patients with CVD, those undergoing biologic therapy had lower abundance levels of Barnesiellaceae, comparable to those found in patients without CVD. Overall, these findings suggest that the co-occurrence of psoriasis and CVD might be linked to gut microbiome dysbiosis and that therapeutic strategies could help to restore the intestinal symbiosis, potentially improving the clinical management of psoriasis and its associated comorbidities. Full article
(This article belongs to the Special Issue Pathogenesis and Novel Targeted Therapies of Psoriasis)
Show Figures

Figure 1

Back to TopTop